Structure-activity and in vivo evaluation of a novel lipoprotein lipase (LPL) activator
Graphical abstract
Section snippets
Acknowledgements
We wish to thank The Goodyear Corporation, Akron OH for donation of the NMR instrument used in this work. The project described was supported by the National Institute of General Medical Sciences, U54GM104942. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
References (13)
- et al.
Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation
J Am Coll Cardiol
(2008) - et al.
A lipoprotein lipase activator, NO-1886, improves endothelium-dependent relaxation of rat aorta associated with aging
Eur J Pharmacol
(1998) - et al.
A novel Lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4)
Bioorg Med Chem Lett
(2014) - et al.
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute
Circulation
(2006) Increasing HDL Cholesterol Levels
N Engl J Med
(2004)Hypertriglyceridemia: changes in the plasma lipoproteins associated with an increased risk of cardiovascular disease
Am J Cardiol
(1999)
Cited by (13)
A triple combination strategy of UHPLC-MS<sup>n</sup>, hypolipidemic activity and transcriptome sequencing to unveil the hypolipidemic mechanism of Nelumbo nucifera alkaloids
2022, Journal of EthnopharmacologyCitation Excerpt :Lipoprotein lipase (LPL) played a key role in glucose and lipid metabolism, which had been further proved as a crucial regulatory protein to firmly regulate the plasma TG metabolism. It could catabolize lipoproteins accumulated by TG such as very-low density lipoproteins (VLDL) and chylomicrons (Geldenhuys et al., 2017). According to the results of transcriptome sequencing analysis, the expression of gene ANGPTL4, an inhibitor of LPL, was reduced after being affected by O-nornuciferine (Lichtenstein et al., 2007; Sukonina et al., 2006).
Studies on the lipid-regulating mechanism of alisol-based compounds on lipoprotein lipase
2018, Bioorganic ChemistryCitation Excerpt :LPL, a 60 ku glycoprotein, consists of 448 amino acid residues. Its secondary structure has not yet been elucidated and may contain two domains: the N-terminal domain (NTD) and the smaller C-terminal domain (CTD) [26]. There is a near-spherical domain at the N-terminus (1–312 residues), consisting of a beta-linked structure, which regulates the binding of LPL to the substrate.
Novel compounds that target lipoprotein lipase and mediate growth arrest in acute lymphoblastic leukemia
2018, Bioorganic and Medicinal Chemistry LettersTriglyceride-Rich Lipoproteins
2018, Cardiology ClinicsCitation Excerpt :All compounds increase LPL activity but by different mechanisms. NO-1886 primarily increases adipose LPL messenger RNA levels, whereas C10d directly affects the hydrolytic activity and 50F10 stabilizes the active homodimer structure of LPL.50 All have been tested in rodent models and decrease elevated TG; however, clinical development of NO-1886 was terminated because of side effects.
High-content screen using zebrafish (Danio rerio) embryos identifies a novel kinase activator and inhibitor
2017, Bioorganic and Medicinal Chemistry Letters